Naturex and Adamed agree to licensing agreement for Aronox® aronia extract
Naturex positions itself to become the global leader in aronia-based nutraceuticals
PIENKOW, Poland, AVIGNON, France and SAGAMORE, Massachusetts April 06, 2016 – The Naturex group, the world leader in specialty plant-based natural ingredients and Adamed Consumer Healthcare SA., a Polish producer of Over-the-Counter drugs and dietary supplements have signed a cooperation agreement to an exclusive global license for Aronox® aronia extract.
Aronia’s promising health benefits
Aronox® is an extract of the native North American superfruit, aronia. Since 2005, the health benefits of Aronox® have been investigated in seven human clinical studies. The outcome of these studies have shown very promising results in a variety of health related areas including the reduction of cardiovascular risk factors, the improvement of blood flow and the decrease of oxidative stress. Aronia, also called black chokeberry, possesses a unique combination of phytonutrients and is particularly high in polyphenolics that help maintain cardiovascular health. However, new research has also shown aronia to hold potential in the areas of anti-inflammation, blood glucose management and improved blood flow which could positively impact vision, cognitive performance and muscle oxygenation and recovery.
Increasing technical solutions and value-added offerings for customers
In 2010, Adamed Consumer Healthcare S.A. was formed after the acquisition of Agrophram S.A., the Polish developer of Aronox®. At that time, Adamed Consumer Healthcare and the Aronox® clinical dossier became part of the Adamed Group, a leading Polish pharmaceutical and biotechnology company.
As licensee, NATUREX has been given global exclusive rights to use the Aronox® clinical dossier and trademark and to sublicense it to its B2B customers in all territories where the trademark has been registered. Only four eastern European countries and Spain will be excluded from this agreement.
Aronox’s addition to the NATUREX’s portfolio of new botanical extracts with a clinical dossier will enable the group to expand its market presence and strengthen its position in the development and sales of technical solutions with value-added offerings for its customers. Marc Roller, Chief Scientific Officer for NATUREX, commented: “This partnership with Adamed is part of Ingenium, our new Open Innovation Program. Aronox® will further enhance our global leadership position in the phytoactives market segment, one of four key categories highlighted in our Bright2020 strategic plan, with various applications that will help our customers reduce time to market, fitting perfectly with consumers’ expectations.”
Naturex is the global leader in specialty plant-based natural ingredients. Through its dedicated business units, the Group addresses the specific needs of three strategic markets: Food & Beverages, Nutrition & Health, and Personal Care. The company offers its customers a full array of high-quality ingredients, responsibly sourced from nature for food, nutraceutical and cosmetic applications. Naturex’s head office is in Avignon, France. The company employs more than 1,700 people and benefits from eight sourcing offices around the world and high-performance manufacturing operations across 15 sites in Europe, Morocco, the United States, Brazil, Australia, India, and Chile. It also has a global commercial presence through a dedicated network of 25 sales offices.
Your Naturex contacts:
Group Marketing Director
Tel: +334 90 23 96 89
Media Relations Manager
Tel : +33 (0)4 90 23 96 89
The Adamed Group is a Polish pharmaceutical and biotechnology company manufacturing over 250 products offered to patients in nearly 60 countries around the world. Currently, it has 1,600 employees. Since 2000, the company has invested EUR 225 million in research and development. It establishes scientific research consortia with leading universities and scientific institutes. The company’s intellectual property is protected by over 90 patents. The Adamed Group is rated by among ten largest pharmaceutical companies operating in Poland. The company was a pioneer in the country when in 2001 it began research on innovative drugs. Less than four years later, jointly with the Jagiellonian University, it initiated one of the first industry–academia consortia in Poland. Nowadays over 150 scientists from leading Polish academic centres collaborate with the Adamed Group in the search for effective therapies.
Your Adamed contacts:
Senior Area Manager
Tel.: +48 513 000 393
Tel.: +48 601 925 328